Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Standardizing Treatments for Pulmonary Exacerbations: A Platform for Evaluating Treatment Decisions to Improve Outcomes (STOP360) Aminoglycoside Study (AG Study)

NCT05548283 is registered in ClinicalTrials.gov with Chris Goss as lead sponsor.

NCT NCT05548283
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05548283 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Standardizing Treatments for Pulmonary Exacerbations: A Platform for Evaluating Treatment Decisions to Improve Outcomes (STOP360) Aminoglycoside Study (AG Study)
Lead sponsor
Chris Goss
Phase
Phase 4
Overall status
Recruiting
Start date
April 23, 2023
Completion date
May 31, 2027
Enrollment
730 (estimated)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis, cystic fibrosis pulmonary exacerbation